Table 4. Subgroup analyses of pooled HRs for progression-free survival.
| Study | No. | HR (95% CI) | Z | p-value | I-squared (%) | p-value | |
|---|---|---|---|---|---|---|---|
| Publication year | |||||||
| 2004–2014 | 4 | 1.804 (1.299–2.506) | 3.52 | 0.000 | 50.8 | 0.107 | |
| 2015–2016 | 4 | 1.409 (1.237–1.606) | 5.16 | 0.000 | 31.1 | 0.226 | |
| Country | |||||||
| Asia | 4 | 1.457 (1.202–1.767) | 3.83 | 0.000 | 39.8 | 0.173 | |
| America | 4 | 1.613 (1.253–2.075) | 3.71 | 0.000 | 59.5 | 0.060 | |
| Case number | |||||||
| <500 | 4 | 2.015 (1.567–2.595) | 5.46 | 0.000 | 0.0 | 0.762 | |
| >500 | 4 | 1.377 (1.229–1.544) | 5.50 | 0.000 | 21.5 | 0.281 | |
| Category | |||||||
| Ovarian cancer | 3 | 1.625 (1.057–2.496) | 2.22 | 0.027 | 60.7 | 0.111 | |
| Epithelial ovarian cancer | 4 | 1.529 (1.319–1.774) | 5.61 | 0.000 | 0.0 | 0.611 | |
| Advanced epithelial ovarian cancer | 1 | 2.310 (1.499–3.559) | 3.80 | 0.000 | - | - | |
| High-grade serous ovarian cancer | 1 | 1.210 (0.993–1.474) | 1.89 | 0.059 | - | - | |
| Clinical stage | |||||||
| I–IV | 6 | 1.401 (1.267–1.550) | 6.58 | 0.000 | 5.3 | 0.383 | |
| III–IV | 2 | 2.271 (1.618–3.186) | 4.75 | 0.000 | 0.0 | 0.901 | |
| Cut-off | |||||||
| >300 | 1 | 1.681 (1.079–2.619) | 2.29 | 0.049 | - | - | |
| >350 | 1 | 2.210 (1.281–3.813) | 2.85 | 0.004 | - | - | |
| >400 | 4 | 1.603 (1.329–1.934) | 4.94 | 0.000 | 43.4 | 0.151 | |
| >450 | 2 | 1.242 (1.056–1.461) | 2.61 | 0.009 | 0.0 | 0.653 | |
| Cut-off* | |||||||
| >300 | 1 | 1.681 (1.079–2.619) | 2.29 | 0.022 | - | - | |
| >400 | 4 | 1.481 (1.308–1.676) | 6.20 | 0.000 | 0.0 | 0.462 | |
| >450 | 2 | 1.242 (1.056–1.461) | 2.61 | 0.009 | 0.0 | 0.653 | |
CI, confidence interval; HR, hazard ratio.
*Only for I–IV patients.